25
Participants
Start Date
January 31, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
BIBF1120
Tablet 200 mg twice daily until progression
Rigshospitalet, Copenhagen
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
University of Copenhagen
OTHER
Ulrik Lassen
OTHER